Kabra Drugs Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Kabra Drugs Ltd is ₹ 23.63 as of 12 Jun 15:30 . The P/E Ratio of Kabra Drugs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 26.1 on March 2022 to 31.4 on March 2025 . This represents a CAGR of 4.73% over 4 years The Market Cap of Kabra Drugs Ltd changed from ₹ 2 crore on March 2022 to ₹ 26.27 crore on March 2025 . This represents a CAGR of 90.37% over 4 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 3967 crore on March 2022 to ₹ 5903 crore on March 2025 . This represents a CAGR of 10.45% over 4 years The revenue of Kabra Drugs Ltd for the Mar '26 is ₹ 35.52 crore as compare to the Dec '25 revenue of ₹ 30.6 crore. This represent the growth of 16.08% The revenue of Supriya Lifescience Ltd for the Mar '26 is ₹ 280.01 crore as compare to the Dec '25 revenue of ₹ 209.05 crore. This represent the growth of 33.94% The ebitda of Kabra Drugs Ltd for the Mar '26 is ₹ 1.45 crore as compare to the Dec '25 ebitda of ₹ 2.62 crore. This represent the decline of -44.66% The ebitda of Supriya Lifescience Ltd for the Mar '26 is ₹ 101.1 crore as compare to the Dec '25 ebitda of ₹ 74.24 crore. This represent the growth of 36.18% The net profit of Kabra Drugs Ltd changed from ₹ -0.55 crore to ₹ 1.06 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 74.23 crore over 8 quarters. This represents a CAGR of 28.95% The Dividend Payout of Kabra Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Kabra Drugs Ltd

Kabra Drugs Limited was incorporated as a Limited Company on August 22, 1989.
The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical.
The commercial production commenced in 1991.
Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.
The Company has 500+ products across India. The Company was incorporated with a mission to enrich the lives through pharmaceutical solutions which are innovative, high-quality and accessible to every family it serves.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Kabra Drugs Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Kabra Drugs Ltd or Supriya Lifescience Ltd?

Market cap of Kabra Drugs Ltd is 56 Cr while Market cap of Supriya Lifescience Ltd is 7,876 Cr

What are the key factors driving the stock performance of Kabra Drugs Ltd and Supriya Lifescience Ltd?

The stock performance of Kabra Drugs Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kabra Drugs Ltd and Supriya Lifescience Ltd?

As of June 14, 2026, the Kabra Drugs Ltd stock price is INR ₹23.63. On the other hand, Supriya Lifescience Ltd stock price is INR ₹978.65.

How do dividend payouts of Kabra Drugs Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Kabra Drugs Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.